Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Settings
Settings
Dynamic quotes
OFFON

school135perm Homepage > Equities > Nasdaq > Amgen AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions
News SummaryMost relevantAll newsSector newsTweets

Amgen : estimates its U.S. tax bill at over $6 billion as it repatriates cash

0
12/22/2017 | 11:10pm CET
An Amgen sign is seen at the company's office in South San Francisco

Amgen Inc said it expects to incur tax expenses of $6 billion to $6.5 billion over time as it repatriates cash it has accumulated around the world because of the new U.S. tax law signed by President Donald Trump on Friday.

Some of the expense is also due to the revaluation of its tax liabilities, the drugmaker said in a filing with the Securities and Exchange Commission.

Amgen did not say how much of its $38.9 billion in cash and other holdings it plans to move back to the United States. To encourage U.S. companies to bring home the more than $2.6 trillion now held overseas, the law sets a one-time tax repatriation rate of 15.5 percent for cash and cash-equivalents and 8 percent for illiquid assets.

Amgen said its future U.S. income generally will be taxed at the 21 percent U.S. corporate income tax rate, while its income elsewhere will generally be taxed in the United States at 10.5 percent, reduced by foreign tax credits.

It said the tax expenses from moving its cash back to the United States will affect its current generally accepted accounting principles (GAAP) earnings forecast, but will not affect its non-GAAP forecast.

(Reporting by Michael Erman; Editing by Lisa Shumaker)

0
Latest news on AMGEN
06:09pAMGEN : New Biologics Findings from Amgen Described (Accelerating patient access..
01:33pAMGEN : European Medicines Agency Accepts Filing for EVENITY
01:33pAMGEN : Astellas BioPharma K.K. - Application for Marketing Approval Submitted f..
01/09U.S. pharma executives expect deals to pick up after tax overhaul
01/09UCB : European Medicines Agency Accepts Filing for EVENITYTM
01/08AMGEN : European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab..
01/05AMGEN : FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related E..
01/04AMGEN : Patent Application Titled "Process for Manipulating the Level of Glycan ..
01/04AMGEN : Researchers Submit Patent Application, "Stable Frozen Virus Formulation"..
01/04AMGEN : Studies Conducted at Amgen on Immunoglobulins Recently Reported (High-th..
More news
News from SeekingAlpha
01/10Top Reasons To Put Your Money In AbbVie In 2018
01/10Amgen (AMGN) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slid..
01/10Nasdaq 'Safer' Dividend Gainers Led By Western, Vodafone, And Broadcom As Per..
01/10When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
01/10Top Nasdaq Gainers Are Western Digital, Vodafone And Broadcom Per January Bro..
Financials ($)
Sales 2017 22 895 M
EBIT 2017 11 764 M
Net income 2017 8 360 M
Finance 2017 6 824 M
Yield 2017 2,47%
P/E ratio 2017 16,44
P/E ratio 2018 16,18
EV / Sales 2017 5,50x
EV / Sales 2018 5,31x
Capitalization 133 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | school135perm
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 192 $
Spread / Average Target 5,1%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN5.45%132 740
JOHNSON & JOHNSON1.55%386 778
NOVARTIS AG3.11%223 039
PFIZER0.64%217 387
ROCHE HOLDING LTD.1.34%217 005
MERCK AND COMPANY0.94%156 277
Copyright © 2018 Surperformance. All rights reserved.